Nutrition and Health Function
Effect of Dietary Ceramide and Glucosylceramide on the Alleviation of Experimental Inflammatory Bowel Disease in Mice
2022 Volume 71 Issue 9 Pages 1397-1402
Details
2022 Volume 71 Issue 9 Pages 1397-1402
Ceramide prepared from glucosylceramide (GlcCer) with Gluceribacter canis NATH-2371T was administrated to inflammatory bowel disease (IBD) model mice. Dietary ceramide significantly suppressed the decrease in final body weight, and the increase in the disease activity index and myeloperoxidase activity more greatly than GlcCer in IBD mice. Intestinal microbiome profiles were found to be altered in IBD mice, but ceramide counteracted the changes. These results suggest that dietary plant-based ceramide may alleviate symptoms of IBD in mice.
